speaking Ugur. with today. Glad you, Thank to everyone
Our novel multi-platform our key pipeline for of is consider to clinical source a a continuing and that And it to is novel, grow we pillar rationally strategy. rich planned progress. a combinations
namely modalities, As so our assets priority to in attention. X I immunomodulator special Today, modalities, mRNA are focus is clinical and have advanced on our in dominantly of want particularly you pipeline, stages. can and represented see, our which within these the
X which I Before that assets, you plans these as me are and building vaccines -- of our on pipeline are slide, execution mRNA capability, a let clinical compounds, IO can ambitious see continuously we wide require we Our last rich we and cover clinical mention just of to Xx quarter pace enrollment previous quarter into to on our patients XXXX, patient and pipeline are accruals accelerating the partners trials slide. recruiting you support saw the now compared the compared to of network as many per the
year our as to testament product and and complement access in trials multiple trial not and compounds additional a larger which geographic our pipeline, strategy. of mid- late-stage clinical of to us is increase underlines drive gives by leverage partnership towards to capacity that launches XXXX. ambition achieve the of only success reach. oncology know-how our part execution more own also us but It our the to enables This
X iNeST Now center neoantigens an antigens to to cancer which and are type derived tumor vaccine cancer of of and our portfolio, computational with personalized of FixVac, antigens shared are approaches are nonmutated that oncology given unique target discover select a of our competencies. tumor. of type antigens core tumor iNeST mRNA target X target. patient. individual they on-demand multiple to differ target different piece off shelf. the each somatic and a a to our and by in majority for types mutations these manufactured individual platforms, patients in vaccines The are sets
Today, indications technology, vaccine disease across LPX our have FixVac ongoing iNeST both proprietary the trials platforms. namely use both same multiple mRNA and and settings in platform. we
multiple have across have reported reported clinical past and in data the compound LPX that years Aggregate and data translational slide future mild We couple shown have the a updates over the vaccines based manageable in chemotherapy. profile and indicate we anti-PD-X trials last of a from data and with with trials FixVac safety largely mRNA PD-LX and combination combination that uridine single iNeST agent in on
functional responses vaccines expanding from a and and sample long-lived Furthermore, clinical which combination Our prerequisite clinical proficient data size cell PD-LX majority of anti-PD-X, our cohorts in in also alone indicates magnitude, high Urogen patients, mRNA small with indicates our data patient T inducing that in based treatment. are activity. is activity the for and
answer on to right, aim multiple slide this In standard to mRNA whether metastatic of on evaluated shown trials material ongoing respective X in being and adjuvant now currently the are would the vaccines setting. trials of highlight of FixVac superior our both Several in question program vaccine to here candidates like the the the care. I our
in a randomized well being trial. Phase BNTXXX cell first-line head PD-LX-positive potentially underway registrational HPVXX-positive First, squamous in neck carcinoma II
populations not collectively and that least, different Second, NT non-small XXX melanoma than more cancer, cover encodes or agent last a BNTXXX investigated -- XX% single immunogenic. mRNALPX-based lung melanoma lines. I and combinations but patient cell to that the like which Urogen being melanoma, about investigated in BNTXXX as patients talk and would relapsed are bit and in various X antigens trials more refractory treatment anti-PD-X vaccine the in highly And being X of associated is
partner, total of are compound, patients evaluating we Stage Phase II or measure a III Stage our in and In alone PD-LX IV of silicimabalon randomized or melanoma. BNTXXX Regeneron's X-arm trial the we with conducted collaboration activity the enrolled Regeneron, in cemiplimab, with in with XXX clinical unresectable anti-PD-X refractory combination
endpoint, Ugur historical cemiplimab the primary rate announced a its response very As in relapsed BNTXXX patients. statistically the earlier, arm improvement as we control to in overall of compared refractory trial achieving of noted combination recently met monotherapy that anti-PD-X significant
multiple inhibitors control for patient the population. objective response historic this based expected in setting checkpoint this rate on trials late-stage clinical for that established The was monotherapy
advanced checkpoint the we the trend a While maturing, population. treatment inhibitors overall based patients on dose with BNTXXX who further initial early the with agent towards survival. efficacy Phase established trial see and single improved trial options. The melanoma do BNTXXXXX this provided is are trial and I/II data The immunogenicity approved have on in patient safety, adipomeric in data a and exhausted
anti-PD-X observed antigen proof-of-concept with study, we of T that against at treatment least tumor-associated were not high-magnitude alone or in prior using all the time most BNTXXX vaccine. in In with analyzed patients, combination could detectable induce which to X strong that responses cell
those for As were generally co-treated years. expectations profile mild followed up for inhibitors. patients shown patients in with were durable here, with who some objective BNTXXX checkpoint safety responses was line and several by The with
The analysis from with results a Phase seeing BNGXXX-XX We are the are II the plan to study present at full medical in conference primary we consistent results. prior these data the into entering forward are and incidence and a and discussions with mortality high-end XXXX for melanoma regarding regulatory path increasing in Cutaneous this program. word. clinical our authorities continuous carries the data
eligible, a therapies only furor of response salvage medical be patients we the potentially achieve interest leaving do In that context, of checkpoint responses unmet patients limited introduction this for in new of is The after be short-lived standard inhibitors, treat our checkpoint may to high available therapy, has survival. need in expect unaddressed. that to stages survival all while established BNTXXX patient for improvements medical have population, need Nonetheless care become population. directed a was led significant a no with long-term adopted patients not long-term a this will a strategy advanced recently significant and disease to failure breakthrough and of there inhibitor only
free data BNTXXX the Moreover, in concept proof dimensions. of is a
is Firstly, noncoding our systemic concept uses cancer a for performance and translational delivery. origin a that vaccine mRNA that our proprietary optimal lipoplex mRNA improved engineered proof technology chemistry for of formulation for backbone
concept a targets program suitable is for this our of antigens Second, our X-leg computational cancer indication-specific for selecting tumor and proof candidates. approaches for
cancer individualized the on case, this concept based immune these And and a medical adjuvant to resectable or cancer We also as in X proof residual of an unmet with BNTXX breakthrough immunotherapy platform addressing BNTXXX, synergistic modalities. ILS combine in and settings. to it's our of established need strategy same lastly, individualized a treatment disease cancer of minimal consider our the checkpoint mRNA All inhibitor our treatment. delivery In for technology. high medical vaccines applies
to resection XX% want II ongoing relapse appear alone I adjuvant after in XX% adenocarcinoma up is for with to trials treatment. ductal X though to after Here, within years colorectal The carcinoma you rate in pancreatic of and more vaccine our X-year individualized highlight pancreatic randomized and adenocarcinoma cancer. pancreatic in survival Phase patients ductal ductal with they even
X relapsed therapy. X Stage resection high-risk after and for colorectal As X or adjuvant patients XX% of years cancer, within Stage about
As we cancer that a discussed in reduced individual are cancer individualized -- demonstrated for cell responses mutant was induce in can the patients last with used neoantigens of vaccine adjuvant our patients specific the immune tumor T earnings responses of the and the period. that even vaccine-induced to recurrence after that pancreatic with follow-up call, risk X-year novo
care chemotherapy. of IAS At ESMO disclosed cancer X high-risk with localized sub adjuvant BNTXXX-XX, excision remain our of the completion involving colorectal the upon GI Phase ctDNA-positive biomarker cancer conference, following patients we who prior of of stage recent from II the findings of study surgical X ongoing the standard a
vaccine the cell responses flow. approach. with de of observed These were immunogenicity X a subset contrast BNTXXX sustained high vaccination cell years even response T encoded These T patients success X were in novo the were in patients all after to was of least several vaccine responses patients. patients, cell accessible neoantigen Notably, T who of wait-and-watch in conventional amplified for cycles the magnitude against at our received In individualized analysis,
XXXX at All study of underway part establish the the XX patients the 'XX. study involved cancer corrector or disease-free to I main immunogens the patients safety this in cancer standard for DNA opposed Enrollment Day of with Phase wait-and-watch as cutoff. BNTXXX is remain early and from data Stage in analysis the positive II of We detected efficacy anticipate by randomized the strategy. time presenting to results the
vaccine our Phase vaccines to our bulk capacities on supply fixed capabilities ongoing and are also up manufacturing immunotherapies for for multiple and mature, As mRNA and trials RNA II clinical off-the-shelf data are drug continues potentially we scaling we in facility capacity individualized Germany out pilot the program currently personalized building future support in commercialization. and late-stage mRNA, are our manufacturing Mainz, our ongoing our to build for to a for trials
key improving continue for to now with mRNA our vaccines, a compound, BNTXXX AI wholly also in work From mRNA we consider to BLTXXX, our as to moving leverage our the and immunomodulatory manufacturing. IO owned up both in in security teams which validated backbone of study We company and processes combination. action. specifically cancer combines I'm novel concept hub mechanisms downstream immunomodulatory X compelling personalized our
to exhaustion. block antibody cell tumor the A and VEGF tumor may VEG X binding PD-LX by also proliferation efficient reverting tumor more the bed for PD-LX arm tumor of and side the of axis T-cell of A localized despite A PD-LX, target to the VEGF inhibitor PD-X formation bispecific A, mediated contribute scavenging arm a anchors mitigate to with inhibition survival. micro VEGF-R antibody leads VEGF contract scenes, which effects. and which also on The reduced does immunosuppressive environment of as specific
as a A VEGF cases, some types both tumor in and across where the combination. anti mechanisms that PD-X many Given are and validated entire
of have ahead BNTXXX. where develop to We a map clear us road
standard up activity. indications new for our range partner, combine of combinations combinations, to plan started and treated care we chemotherapy, the XXX XXX open patients which evaluate with and If of the initial novel these anti-VGFA recently. may across indications have anti-PD-LX may first We clinical in our the of were Novel with Beyond over which we Biotheus of wide BNTXXX. areas
a and for various extensive informed protocols. registration foundation cohorts standard with effort combination potential making This in decisions or data solid future studies. Monotherapy of collection on patient provides care data-driven for indications
rates adverse XX% anti-VEGF responses objective agents. with specifically in cancer standard response in small lung when favorable observed first safety generally be other we managed previously untreated breast triple-negative with and The cell cancer of events activity in Notably, rate in approaching lung combined appears observed combination PD-LX robust targeting chemotherapy well seen with non-small single-agent durable therapies triple-negative high those the indications was and cell cancer and more BNTXXX with with profile advanced to than cancer, these an breast response line, line data with and in demonstrates in
lung cancer, of only inhibitors, our achieved next non-small beyond cancer cell breast cell lung and trials data therapeutic around year small which These initiate cancer this approaches small in response year. the in few innovative with metastatic remain disease cell registration driven strategic lung anti of for In treatment cancer limited have frontline rates and PD-X to decision options triple-negative checkpoint XX%.
anti-PD-X TNBC do with negative metastatic these have In patients, Nearly tumors half frontline are cell options combination of chemotherapy. PD-LX for while anti-PDX current lung not therapy they with particularly changed have cancer, treatment eligible not patients in treatment the therapies. those few significantly as respond they inhibitors to non-small landscape.
Phase We these global particular enable will selection a II registrational studies trials global still of to registrational X for dose dose optimization indications. start in
presented advanced cohorts cancer, ASCO, preliminary updated and cancer. ovarian At platinum-resistant I/II we study non-small ongoing in data lung an Phase of from advanced relapsed efficacy cervical safety and cancer cell
be indications and We from plans database of our indications. will additional to signal for is at basis presenting key upcoming in further finding the conferences. add extensive This our will tumor data development
Most importantly, BNTXXX therapies. mRNA goal strategic to as of novel novel, is ADC particular, Ugur also part explore for a noted, and us with combinations our as assets in it
implement BNTXXX, We BNTXXX to have strategy coming with months. our further investigating combinations be announced started combination by the in in will this
very advance with combination excited these trials our to are We partner.
an will and safety have trial. other findings BNTXXX and mainly trials from immunogenicity carcinoma, cervical X on II the anal on here, include annual update some update we our we assets. slide outlook Phase HPVXX final an with now, of and report the first evaluating on net Barcelona, our my I present September On will like presentation Congress At priority would our in upcoming ESMO provide to Congress in updates patients with
Phase alone with versus dose will head This run-in carcinoma. remoter softer with HPVXX safety, from update cohort trial finding II positive on in second include court. of perlizumab, evaluating safety the a focus pembrolizumab preliminary immunogenicity BNTXXX patients our and ongoing activity will The update neck combination
tumors. on in lung update a also monotherapy results with non-small our different patients on cancer ongoing cell our present partner, I be efficacy combination updated VEGF-R-mutated initial with with as regimens. BNTXXX And vaccine either We evaluating BNTXXX Biotheus efficacy presenting the results will safety we will a and trial, follow from cell in combination patients finally, updates of and mRNA with relapsed contain these and of as T were TNBC with our updated together and refractory with CAR will safety in Phase
will follow-up presented updated safety and what a Congress on as be efficacy year's assistant. data cell was This as last will from CAR include well at data ESMO data and T
future. We near now will presentation will to and these share complications I additional further pass congress CFO, the With details Jens in that, Holstein. on the our
